PTC Therapeutics, Inc. (PTCT) Stock

PTC Therapeutics, Inc. (PTCT) is a Healthcare stock trading at $69.86 (as of 2026-08-21), with a market capitalization of $5.83B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

PTC Therapeutics, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing therapies for patients with rare disorders. It markets products such as Translarna, Emflaza, Tegsedi, Waylivra, and Evrysdi across multiple regions, and it has product candidates in clinical, pre-clinical, and research stages, including PTC518.

Understand PTC Therapeutics, Inc.: how it makes money

PTC Therapeutics discovers, develops, and commercializes medicines for patients with rare disorders, and makes money primarily from selling its commercial products, with additional revenue from royalties, collaboration, and milestone items.

Near-term profitability is driven by recurring net product sales from PTC's commercial rare-disease portfolio (including medicines like Translarna and Emflaza), while additional revenue can come from collaborations and milestone events.

Revenue by segment (latest quarter)
Commercial products$0.2B
Milestones$0.1B

Business quality (Exceptional): Revenue appears to be split between product sales and milestone-related items, so understanding execution in commercial products and the timing of non-product payments is key, with added uncertainty from the earlier-stage pipeline.

Bull case

  • Commercial product base exists in rare disease: PTC offers Translarna and Emflaza for Duchenne muscular dystrophy (in the European Economic Area and the United States), which supports net product revenue generation.
  • Non-product revenue streams can add upside: Revenue candidates include Royalty, Collaboration and License Revenue and milestone revenue, which can contribute beyond product sales.

Bear case

  • Revenue can be affected by mix shifts between product and non-product items: The model includes both net product revenue and milestone-related revenue, so results may vary depending on the timing and amount of milestone events.
  • Pipeline outcomes are uncertain: PTC has product candidates in clinical, pre-clinical, and research and discovery stages, and not all pipeline programs may successfully progress to commercialization.
Valuation — source: SEC EDGAR (first-party)
Price$69.86
Market Cap$5.83B
EV / EBITDA29.6
Price / Sales5.78
FCF Yield-0.7%
DCF Value (model)$156.53
DCF Upside vs Price124.1%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$1.73B
Net Margin39.4%
Revenue Growth (YoY)101.5%
EPS Growth (YoY)-221.7%
FCF Growth (YoY)-312.8%
Financial Health — source: SEC EDGAR
Altman Z-Score1.81 (grey)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBlackRock, Inc. ($882.20M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOMatthew Klein
Employees939
CountryUS
IPO Date2013-06-20

Related Companies (Pharmaceutical Products; 8 comparable drugmakers)

  • Sarepta Therapeutics, Inc. (SRPT)
  • Royalty Pharma plc (RPRX)
  • Indivior Pharmaceuticals Inc (INDV)
  • Lakefront Biotherapeutics NV (LKFT)
  • Prestige Consumer Healthcare Inc. (PBH)
  • ACADIA Pharmaceuticals Inc. (ACAD)
  • Amneal Pharmaceuticals, Inc. (AMRX)
  • Ionis Pharmaceuticals, Inc. (IONS)
PTCT earnings history · PTCT institutional & insider holders · PTCT KPIs & operating metrics · PTCT financials · PTCT investor presentations & press releases · PTCT SEC filings · PTCT peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.